Research programme: antiviral therapeutics - IRX Therapeutics

Drug Profile

Research programme: antiviral therapeutics - IRX Therapeutics

Alternative Names: IRX-3

Latest Information Update: 18 Jan 2011

Price : $50

At a glance

  • Originator IRX Therapeutics
  • Class Cytokines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical HIV infections; Human papillomavirus infections

Most Recent Events

  • 18 Jan 2011 IRX 3 is still in preclinical development for Human papillomavirus infections in USA
  • 18 Jan 2011 IRX Therapeutics completes preclinical development in HIV infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top